A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Bristol-Myers Squibb
Bristol-Myers Squibb
Hoffmann-La Roche
Vejle Hospital
University of Texas at Austin
Otsuka Australia Pharmaceutical Pty Ltd
Indiana University
Bispebjerg Hospital
Chinese University of Hong Kong
Dana-Farber Cancer Institute
Norwegian University of Science and Technology
University of Pennsylvania
University of Pittsburgh
Novartis
Boston Medical Center
VA Office of Research and Development